A Phase I Pilot Trial to Evaluate the Toxicity of Epstein-Barr Virus Specific T-Lymphocytes or Peripheral Blood Mononuclear Cells for the Treatment of Relapsed/Refractory Hodgkin's Disease
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Epstein-Barr virus-specific cytotoxic T lymphocytes (Primary) ; Fludarabine; Interleukin-2
- Indications Hodgkin's disease
- Focus Adverse reactions; Pharmacodynamics
- 18 Dec 2013 Biomarkers information updated
- 24 May 2012 Additional lead trial centres added as reported by ClinicalTrials.gov.
- 03 Sep 2005 New trial record.